Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool September 6, 2011 Brian Orelli	Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game?
The Motley Fool July 9, 2009 Brian Orelli	Yes! It Can Handle the Pressure Rigel Pharmaceuticals' latest tests show that the side effects from its rheumatoid arthritis drug candidate R788 are manageable.
The Motley Fool December 22, 2009 Brian Orelli	Some Incyte Into Why These Drugs Rock Eli Lilly jumps on the oral-drug-for-rheumatoid-arthritis bandwagon.
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Rheumatoid Arthritis: JAKing Down Inflammation In the race to market the first oral drug to compete with high-priced injectables for rheumatoid arthritis, Pfizer's tasocitinib has the home-stretch lead over Rigel, Vertex, and Incyte.
The Motley Fool February 17, 2010 Brian Orelli	$1.24 Billion Deal. Shares Fall 9%. That Makes Sense. Rigel Pharmaceuticals signed up AstraZeneca to take over development of its phase 2 rheumatoid arthritis drug, R788, with more than $1.24 billion in potential payments, and the shares fell more than 9%.
The Motley Fool December 14, 2010 Travis Hoium	Lexicon Pharmaceuticals Shares Plunged: What You Need to Know Lexicon Pharmaceuticals shares fell as much as 14% in intraday trading on disappointing results of its rheumatoid arthritis drug test.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool December 14, 2007 Brian Orelli	An Overnight Three-Bagger It's not often you see stocks triple in one day, but that's what Rigel Pharmaceuticals did. You might be surprised, however, as to why. Investors, take note.
The Motley Fool June 13, 2008 Brian Orelli	Some Insight Into Incyte's Data Incyte's rheumatoid arthritis drug looks promising, according to early numbers.
The Motley Fool January 7, 2011 Brian Orelli	A Biotech Roller Coaster Lexicon is back on the upswing.
The Motley Fool June 15, 2010 Brian Orelli	Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer.
The Motley Fool June 26, 2009 Brian Orelli	The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over.
The Motley Fool June 21, 2007 Brian Lawler	Panacos Validates Itself Panacos releases more clinical trial results for an exciting drug. Investors, take note.
The Motley Fool September 9, 2009 Brian Orelli	Weight Down. Stock Price Up. Really Up. Positive phase 3 trials will do that for VIVUS' anti-obesity drug, Qnexa
The Motley Fool July 14, 2011 Brian Orelli	Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial.
The Motley Fool April 29, 2011 Brian Orelli	Nice Efficacy, Pfizer, But... Safety data is most important at this point. Nothing can stop Pfizer's oral rheumatoid arthritis treatment tofacitinib.
The Motley Fool August 31, 2009 Brian Orelli	Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it..
The Motley Fool December 15, 2009 Brian Orelli	Forget the Higher Doses Elan has to drop the highest dose of an Alzheimer's drug. Again.
The Motley Fool June 4, 2008 Brian Orelli	Expanding Possibilities Fail to Expand Rigel's Stock Price Rigel gets positive data on a second indication for its lead drug, R788.
The Motley Fool April 3, 2009 Brian Orelli	Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately.
The Motley Fool June 9, 2010 Brian Orelli	The Drug Passed, but the Stock Fell? Regeneron only bats .500.
The Motley Fool March 16, 2011 Brian Orelli	Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial.
The Motley Fool February 11, 2010 Brian Orelli	A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects.
The Motley Fool May 19, 2010 Brian Orelli	The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd.
The Motley Fool December 19, 2008 Brian Orelli	Open-Label Bites Drug Duo Pfizer and Celldex have to make the best of a bad situation.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool December 5, 2005 W.D. Crotty	Rigel Pharmaceuticals Gets Stomped The biotech tumbles on poor phase 2 trial results for an allergy drug. Until another compound begins to offer glimmers of hope, this stock will probably offer little if any price appreciation.
The Motley Fool November 15, 2011 Brian Orelli	Good Data, Big Drug Market, but Still Risky Eli Lilly's evacetrapib is behind Roche and Merck.
The Motley Fool March 3, 2010 Brian Orelli	A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%.
The Motley Fool April 18, 2011 Brian Orelli	Up 95%! No Anchor Holding Amarin Down The second phase 3 trial of AMR101 deemed a success.
The Motley Fool November 29, 2010 Brian Orelli	Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily.
The Motley Fool March 31, 2009 Brian Orelli	Pharma's Refreshing Bad News Schering-Plough and Eli Lilly both present data at scientific meetings over the weekend about drugs that failed their clinical trials, but it's not bad news.
The Motley Fool May 19, 2010 Brian Orelli	A Potential Blockbuster Bites the Dust. Should You Worry? Despite the gloomy headlines, investors shouldn't be upset that Roche and Biogen Idec have decided to end development of ocrelizumab for rheumatoid arthritis.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool September 21, 2007 Brian Orelli	Size Does Matter BioCryst announces failed phase 2 data with an excuse, and plans phase 3 before year-end. Investors, take note.
The Motley Fool December 14, 2006 Brian Lawler	Vertex: Coming Together Nicely If telaprevir continues to show anything like the 80%-90% rate of undetectable hepatitis C virus at end of its trials, Vertex shareholders won't be dealing with too many more down days.
The Motley Fool December 15, 2011 Brian Orelli	BioSante Shares Crushed by Placebo Effect BioSante's LibiGel efficacy is not deemed statistically significant.
The Motley Fool December 21, 2010 Brian Orelli	Our Drug Is Better Than Your Drug Without a question, Incyte's compound, INCB18424, works in myelofibrosis. Now that it has positive phase 3 results, it's time to get a brand name for the thing; INCB18424 just isn't that catchy.
The Motley Fool December 11, 2009 Brian Orelli	Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze.
The Motley Fool September 11, 2007 Brian Orelli	A Waiting Game for Aspreva It will be three years before Aspreva Pharmaceuticals and partner Roche evaluate results for a treatment for lupus. If and when the drug is approved, it will have to compete with a whole host of other drugs currently in trials. Investors take note.
The Motley Fool April 3, 2009 Brian Orelli	Gilead: Helping Investors Cope With the Market Diversifying seems to be paying off for the drugmaker.
The Motley Fool February 26, 2008 Brian Orelli	The Less-Flashy Prostate Cancer Treatment GTx shows off clinical trial data for a drug that counters the side effects of prostate cancer treatments.
The Motley Fool March 31, 2011 Brian Orelli	Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?
The Motley Fool September 17, 2008 Brian Orelli	Will Denosumab Strengthen Amgen's Bones? Recently passing its phase 3 trial will help get denosumab on the market. But two big questions remain: how well it worked, and whether anyone will buy it, given the drug's plentiful rivals.
The Motley Fool August 10, 2011 Brian Orelli	A Jab a Month Is All We Ask Biogen and Abbott's new long-acting multiple sclerosis drug works, but it has side effects.
The Motley Fool January 22, 2010 Brian Orelli	Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line.
The Motley Fool September 27, 2007 Brian Orelli	Incyte's Double Dose of Trial News With two drugs providing good results in preliminary trials, and another five medications in early-stage clinicals, Incyte is a shining example of a developmental-stage drugmaker. Investors, take note.